Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
about
Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trialsEffect of diuretics on renal tubular transport of calcium and magnesium.Managing and maintaining bone mineral density in diabetes patients with pharmacotherapy.Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
P2860
Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Bone effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
Bone effects of canagliflozin, ...... with type 2 diabetes mellitus.
@nl
type
label
Bone effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
Bone effects of canagliflozin, ...... with type 2 diabetes mellitus.
@nl
prefLabel
Bone effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
Bone effects of canagliflozin, ...... with type 2 diabetes mellitus.
@nl
P2860
P1476
Bone effects of canagliflozin, ...... with type 2 diabetes mellitus
@en
P2093
Thomas C Blevins
P2860
P304
P356
10.1080/00325481.2017.1256747
P407
P577
2016-11-28T00:00:00Z